The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease

Journal of Hypertension

Volumn 23, Issue 8, 2005, Pages 1445-1451

  López, Begoña ^a   González, Arantxa ^a   Querejeta, Ramón ^b   Díez, Javier ^a,c,d  

^a UNIVERSITY OF NAVARRA   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Collagen; Fibrosis; Myocardium; Peptides; Remodeling

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; ENDOTHELIN 1; FIBRILLAR COLLAGEN; FUROSEMIDE; GADOLINIUM; LOSARTAN; MATRIX METALLOPROTEINASE; PEPTIDE; PROCOLLAGEN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SPIRONOLACTONE; TORASEMIDE; TRANSFORMING GROWTH FACTOR BETA;

CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR RISK; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; COLLAGEN SYNTHESIS; CORONARY ARTERY BLOOD FLOW; DISEASE ASSOCIATION; DISEASE MARKER; HEART HEMODYNAMICS; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW;

EID: 23344440581     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000173780.67308.f1     Document Type: Review

References (59)

1. Mutsaers SE, Bishop JE, McGrouther G, Laurent GJ. Mechanisms of tissue repair: from wound healing to fibrosis. Int J Biochem Cell Biol 1997; 29:5-17.
2. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory mechanisms. Cardiovasc Res 1993; 27:341-348.
3. Weber KT. Monitoring tissue repair and fibrosis from a distance. Circulation 1997; 96:2488-2492.
4. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986; 55:575-581.
5. Olivetti G, Melissari M, Balbi T, Quaini F, Sonnenblick EH, Anversa P. Myocyte cellular hypertrophy is responsible for ventricular remodelling in the hypertrophied heart of middle aged individuals in the absence of cardiac failure. Cardiovasc Res 1994; 28:1199-1208.
6. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998; 16:1031-1041.
7. Ciulla M, Paliotti R, Hess DB, Tjahja E, Campbell SE, Magrini F, Weber KT. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: Endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr 1997; 10:657-664.
8. Schwartzkopff B, Brehm M, Mundehenke M, Strauer BE. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 2000; 36:220-225.
9. Brilla CG, Funck RC, Rupp RH. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102:1388-1393.
10. Pardo Mindán FJ, Panizo A. Alterations in the extracellular matrix of the myocardium in essential hypertension. Eur Heart J 1993; 14 (suppl J):12-14.
11. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000; 15:264-272.
12. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. JAMA 1996; 275:1557-1562.
13. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2003; 106:3068-3072.
14. Díez J, López B, González A, Querejeta R. Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol 2001; 16:328-335.
15. Fagard R. Athlete's heart. Heart 2003; 89:1455-1461.
16. Díez J, Querejeta R, López B, González A, Larman M, Martínez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105:2512-2517.
17. Querejeta R, López B, González A, Sánchez E, Larman M, Martínez Ubago JL, Díez J. Increased collagen type I synthesis in patients with heart failure of hypertensive origin. Relation to myocardial fibrosis. Circulation 2004; 110:1263-1268.
18. McLenachan JM, Dargie HJ. Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens 1990; 3:735-740.
19. Schwartzkopff B, Motz W, Frenzel H, Vogt M, Knauer S, Strauer BE. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 1993; 88: 993-1003.
20. Tamirisa PK, Holland MR, Miller JG, Pérez JE. Ultrasonic tissue characterization: review of an approach to assess hypertrophic myocardium. Echocardiography 2001; 7:593-597.
21. Kerut EK, Given M, Giles TD. Review of methods for texture analysis of myocardium from echocardiographic images: a means of tissue characterization. Echocardiography 2003; 20:727-736.
22. Picano E, Pelosi G, Marzilli M, Lattanzi F, Benassi A, Landini L, L'Abbate A. In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation 1990; 81:58-64.
23. Wickline SA, Thomas LJ III, Miller JG, Sobel BE, Perez JE. The dependence of myocardial ultrasonic integrated backscatter on contractile performance. Circulation 1985; 72:183-192.
24. Tandri H, Saranathan M, Rodriguez R, Martinez C, Bomma C, Nasir K. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol 2005; 45:98-103.
25. Nimmi ME. Fibrillar collagens: their biosynthesis, molecular structure, and mode of assembly. In: Zern MA, Reid LM (editors): Extracellular matrix. New York: Marcel Decker; 1993, pp. 121-148.
26. Jensen LT, Host NB. Collagen: scaffold for repair or execution. Cardiovasc Res 1997; 33:535-539.
27. Janicki JS. Collagen degradation in the heart. In: Eghbali-Webb M (editor): Molecular biology of collagen matrix in the heart. Austin, TX: RG Landes; 1995, pp. 61-76.
28. Risteli L, Risteli J. Noninvasive methods for detection of organ fibrosis. In: Rojkind M (editor): Connective tissue in health and disease. Boca Raton: CRC Press; 1990, pp. 61-98.
29. Díez J, Laviades C, Mayor G, Gil MJ, Monreal I. Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 1995; 91:1450-1456.
30. Laviades C, Varo N, Díez J. Transforming growth factor β in hypertensives with cardio-renal damage. Hypertension 2000; 36:517-522.
31. Lindsay MM, Maxwell P, Dunn FG. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002; 40:136-141.
32. Ling YH, Shiau YC, Yen RF, Lin LC, Wu CC, Ho YL, Huang PJ. The relation between myocardial cyclic variation of integrated backscatter and serum concentrations of procollagen propeptides in hypertensive patients. Ultrasound Med Biol 2004; 30:885-891.
33. Díez J, Panizo A, Gil MJ, Monreal I, Hernández M, Pardo Mindán J. Serum markers of collagen type I metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis. Circulation 1996; 93:1026-1032.
34. Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu MJ, Montiel GC, et al. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 1999; 17:107-114.
35. 1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 2000; 35:1197-1202.
36. + exchanger. Cardiovasc Res 2002; 53:862-868.
37. + exchange inhibition. Hypertension 2003; 41:373-377.
38. Laviades C, Varo N, Fernández J, Mayor G, Gil MJ, Monreal I, Díez J. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98:535-540.
39. López B, González A, Varo N, Laviades C, Querejeta R, Díez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001; 98:535-540.
40. Laurent GL. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol 1987; 252:C1-C9.
41. Querejeta R, Varo N, López B, Larman M, Artiñano E, Etayo JC, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000; 101:1729-1735.
42. López B, Querejeta R, Varo N, González A, Larman M, Martínez Ubago JL, Díez J. Usefulness of serum carboxy-terminal propeptide of procollagen type I to assess the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104:286-291.
43. González A, López B, Querejeta R, Díez J. Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease? J Mol Cell Cardiol 2002; 34:1585-1593.
44. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999; 33: 981-986.
45. Seccia TM, Belloni AS, Kreutz R, Paul M, Nussdorfer GG, Pessina AC, Rossi GP. Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J Am Coll Cardiol 2003; 41:666-673.
46. Chen K, Mehta JL, Li D, Joseph L, Joseph J. Transforming growth factor beta receptor endoglin is expresssed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ Res 2004; 95:1167-1173.
47. López B, Querejeta R, González A, Sánchez E, Larman M, Díez J. Effect of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43:2028-2035.
48. Tsutamoto T, Sakai H, Wada A, Ishikawa C, Ohno K, Fujii M, et al. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2004; 44:2252-2253.
49. Uchida T, Yamanaga K, Nishikawa M, Ohtaki Y, Kido M, Watanabe M. Anti-aldosteronic effect of torasemide. Eur J Pharmacol 1991; 205:145-150.
50. Zannad F, Alla F, Dousset B, Perez A, Pitt B, on behalf of the RALES Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Insights from the randomized aldactone evaluation study (RALES). Circulation 2000; 102:2700-2706.
51. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26:809-820.
52. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67:1355-1364.
53. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary aldosteronism. J Mol Cell Cardiol 1993; 25:563-575.
54. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71:12-16.
55. Nicoletti A, Heudes D, Hinglais N, Appay MD, Philippe M, Sassy-Prigent C, et al. Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. Hypertension 1995; 26:101-111.
56. Lacolley P, Safar ME, Lucet B, Ledudal K, Labat C, Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 2001; 37:662-667.
57. Maceira A, Barba J, Varo N, Beloqui O, Díez J. Ultrasonic backscatter and serum marker of cardiac fibrosis in hypertensives. Hypertension 2002; 39:923-938.
58. Ciulla MM, Paliotti R, Esposito A, Díez J, Lopez B, Dahlof B, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis. Results of a randomized trial. Circulation 2004; 110:552-557.
59. Guidelines Subcommittee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.